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Case presentations
Patient 1. A 51-year-old physician was referred to The New York
Hospital-Cornell Medical Center (NYH-CMC) for refractory hyperten-
sion. Two years earlier, a routine physical examination revealed high
blood pressure (200/115 mm Hg). He was treated with hydrochlorothi-
azide, 25 mg daily, but the blood pressure was not reduced, and he
became fatigued; the serum potassium was 3.2 mEq/liter. Methyldopa,
250 mg twice daily, and potassium chloride were added to his antihy-
pertensive regimen, but he subsequently complained of increasing
lethargy and impotence.
At the time of his initial evaluation at the NYH-CMC Cardiovascular
Center, the blood pressure was 202/112 mm Hg, the pulse was 68 and
regular, and the remainder of the examination was normal. The antihy-
pertensive medications were stopped and all side effects resolved
promptly. Laboratory evaluation two weeks later included: normal
electrolytes; BUN, 15 mg/dl; serum creatinine, 1.2 mg/dl; cholesterol,
237 mgldl; HDL, 55 mg/dl; and glucose, 88 mg/dl. Urinalysis and
electrocardiogram were normal. A 24-hour urine collection contained:
sodium, 125 mEq; potassium, 64 mEq; aldosterone, 12 g; and albumin,
48 mg; creatinine clearance was 95 mI/mm. A simultaneous ambulatory
plasma renin activity (PRA) was 6.4 ng/ml/hr. The results of the
captopril test were: pre-captopril blood pressure, 182/112 mm Hg;
pulse, 74 beats/mm; PRA, 4.8 ng/ml/hr; post-captopril: blood pressure,
152/94 mm Hg; pulse, 72 beats/mm; and PRA, 6.8 ng/ml/hr. A captopril
renal scan and a renal artenogram were normal.
Acebutolol was begun in a dose of 200 mg daily. Within two weeks,
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the blood pressure decreased to 132/84 mm Hg; the pulse was 70, and
the PRA was 0.42 ng/mllhr. The 24-hour urine albumin excretion
decreased to 12 mg while the patient was receiving acebutolol treat-
ment. He reported no side effects. This patient's diagnosis, in tradi-
tional parlance, would have been "essential hypertension"; his diag-
nosis in modern parlance is "high-renin, essential hypertension."
Patient 2. A 56-year-old physician was referred to the NYH-CMC for
evaluation of asymptomatic hypertension. First noted to have a blood
pressure of 200/110 mm Hg 5 years earlier, he initially was treated with
propranolol, 40 mg thrice daily. The blood pressure did not change
significantly, and enalapril, 10 mg twice daily, was added, but again
without therapeutic success. The patient developed a chronic, nonpro-
ductive cough.
Initial evaluation at the NYC-CMC Cardiovascular Center revealed a
blood pressure of 196/106 mm Hg and a pulse of 58 beats/mm. The
remainder of the physical examination was normal. Because therapy
was ineffective, all drugs were stopped; one month later, his laboratory
values were: serum sodium, 142 mEq/liter; potassium, 4.1 mEq/liter;
chloride, 102 mEq/liter; TCO2, 26 mmol/liter; BUN, 12 mg/dl; creati-
nine, 0.9 mg/dl; total cholesterol, 212 mg/dl; and HDL, 48 mg/dl.
Urinalysis and electrocardiogram were normal. A 24-hour urine collec-
tion contained sodium, 170 mEq; potassium, 55 mEq; albumin, 8 mg;
and aldosterone, 9 g; the creatinine clearance was 88 mI/mm. A
simultaneous PRA was 0.11 ng/ml/hr. The patient was treated with
nifedipine, 20 mg thrice daily, and his blood pressure fell to 128/82 mm
Hg; the pulse was 84 beats/mm. Felodipine, 10 mg daily, was substi-
tuted for nifedipine, and his blood pressure remained within the normal
range.
The patient's traditional diagnosis would have been "essential hyper-
tension." His modern diagnosis is "low-renin, essential hypertension."
Discussion
DR. JOHN H. LARAGH (Director, Cardiovascular Center;
Chief, Cardiology Division; and Hilda Altschul Master Profes-
sor of Medicine, New York Hospital-Cornell University Medi-
cal Center, New York, New York): The renin-sodium profile,
properly done (as in the two patients presented), is an unusually
accurate and valuable clinical test and is now widely available.
No more expensive than the roster of blood assays convention-
ally employed in the workup of nearly any type of patient, it
should be a routine early step in the diagnosis and management
of all hypertensive patients. Without it, effective, specific,
pathophysiologically based treatment of hypertension cannot
be initiated, except by chance, as the two patients presented
illustrate. Without benefit of the renin-sodium profile or at least
sequential monotherapy, their treatments only intensified their
problems.
Our methodical use of the renin-sodium profile stems from an
appreciation of the central role of the kidney, the fountainhead
of the renin-angiotensin-aldosterone system, in matters relating
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to the regulation of the principal vectors determining blood
pressure: blood volume and arterial vascular tone. In our
clinical practice, the test enables us at the outset to: (1) exclude
or pursue the diagnosis of curable forms of renovascular disease
(renin values over 2.5 nglml/hr) or primary aldosteronism
(values under 1.0 ng/mllhr); (2) plan appropriate drug therapies;
and (3) gain an idea of the pace, severity, and prognosis of the
hypertension, and the likelihood of a heart attack.
The renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone (RAA) system, a set of
interacting and mutually supportive hormones secreted by the
kidney and adrenal cortex, serves simultaneously as a long-
term regulator of (1) sodium balance and extracellular fluid
volume; (2) potassium balance; and (3) effective arterial blood
pressure. The system responds to all influences, external and
internal, that affect any of these three parameters [1].
Juxtaglomerular cells of the afferent arterioles secrete the
enzyme renin in response to a variety of phenomena that reduce
arterial blood pressure, renal perfusion, or the load of sodium
chloride presented to the distal tubule. When renin enters the
blood, it splits off the inactive decapeptide, angiotensin I (Al),
from angiotensinogen (renin substrate). Primarily in the lungs,
but everywhere in the circulation, A! is converted by a circu-
lating and a vascular endothelial enzyme—angiotensin convert-
ing enzyme (ACE)—to the octapeptide angiotensin II (All), the
first effector hormone of the system.
Angiotensin II exerts a powerful, direct, and immediate
vasoconstrictive effect on the arteriolar bed. At the same time it
acts directly on the proximal tubules to increase sodium reab-
sorption. Additionally, at a somewhat slower rate, it stimulates
the adrenal cortex to secrete aldosterone, which then acts on
the distal nephron to retain sodium in exchange for potassium
ions, which are excreted. The retained sodium is responsible for
an accumulation of fluid within the circulation and this in turn
affects blood pressure. The increase in body sodium and plasma
volume also can heighten vascular sensitivity to angiotensin and
affect the level of intracellular calcium, thus inducing additional
vasoconstnctive influences. These multiple effects, dominated
by vasoconstriction, combine to raise blood pressure to the
point where the initial signal for renin release (lowered blood
pressure and renal perfusion), as perceived by renal afferent
arteriolar baroreceptors, is eliminated or dampened.
This interlocking sequence of events prompted the supposi-
tion that an assay of plasma renin activity might reflect the
status of this system in hypertensive patients. Indeed, more
than 20 years of investigation have shown this assay to be the
most reliable indicator of the activity of the system and its
derangement in hypertensive pathophysiology. We believe that
the renin-sodium profile (defined as the relationship of the PRA
to the concurrent 24-hour urine sodium excretion) is basic to
diagnosing the type of hypertension, just as the fasting blood
sugar in relation to plasma insulin is basic to understanding
diabetes. As the blood insulin level must be related to glucose
levels for proper interpretation, the renin assay is most mean-
ingful when related to sodium balance and blood pressure.
Normally, renin secretion reacts stoichiometrically to any
phenomenon that disturbs blood pressure or the balance of
sodium. The level of sodium intake is the most pervasive
exogenous influence to which the renin system must continually
respond. Renin production decreases with increased sodium
intake and increases with decreased sodium intake. With de-
creases in dietary salt and therefore decreased support of blood
pressure by extracellular and blood volume, renin production
rises to marshal its vasoconstrictive and sodium-retaining prop-
erties to the maintenance of normal blood pressure. On the
other hand, increases in dietary salt suppress renin secretion, at
which point body sodium content and ECF volume instead
become the predominant support of blood pressure. Our dem-
onstration of this reciprocal relationship between the plasma
renin level and 24-hour urinary sodium excretion in normal
subjects and in hypertensive patients provided the benchmark
nomograms against which a plasma renin level may be consid-
ered normal or abnormal [11.
While hypertensive patients also exhibit a reciprocal relation-
ship between PRA and urinary sodium levels, these patients
show a much larger degree of variability than do normal
subjects across the entire spectrum, ranging from high-renin!
low-sodium states to low-renin/high sodium states (Fig. 1). The
reciprocal relationship is deranged in slope and exhibits a wider
splay in which 30% of patients have abnormally low plasma
renin values, while some 10% to 20% have abnormally high
values. About 50% of patients with essential hypertension
exhibit renin values within the normal range. However, this
response too is very likely inappropriate and therefore abnor-
mal. The confusion is readily cleared, however, when one
realizes (as we have shown in experimental models) that a renin
level in any hypertensive patient that is equal to that in a
normotensive person with a similar sodium status is not normal
at all [2]. When blood pressure rises for any reason in a normal
person, renal renin production promptly drops to zero or close
to it. Thus any renal renin secretion is abnormal in the presence
of a raised arterial pressure. Accordingly, in hypertensive
individuals, "medium" would be a more appropriate term than
"normal" in categorizing renin levels in the middle range. In
assessing the significance of a given renin level, its relationship
to the 24-hour urine sodium excretion helps to define its
normalcy by evaluating its appropriateness to the dietary salt
intake.
To interpret those relationships, we have found it useful to
employ an analytic model we call "vasoconstriction-volume
analysis" [3, 4]. In this model, we consider that the spectrum of
hypertension is primarily sustained by an inappropriate level of
plasma renin relative to the body sodium content and ECF (the
"sodium-volume factor"). At one extreme of this spectrum of
abnormal plasma renin-sodium products are malignant and
renovascular hypertensions: these diseases are primarily renin-
mediated, "dry," intensely vasoconstricted, high-viscosity hy-
povolemic states, more prone to ischemic injury. At the other
extreme are low-renin, "wet" patients, whose blood pressures
may be even higher but whose lesser vasoconstriction is largely
consequent to retention of sodium and expansion of ECF
volume. These latter patients, such as patients with primary
aldosteronism or low-renin essential hypertension, exhibit rel-
ative hypervolemia and lower plasma viscosity and, therefore,
have higher output and flow states. Medium-renin forms (which
account for approximately 50% of the patients we see) occupy
an intermediate place in the spectrum, expressing inappropriate
amounts of renin activity for the prevailing total body sodium
content, i.e., an abnormal product.
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Fig. 1. Relation of the noon ambulatory
plasma renin activity (A) and of the
corresponding daily urinary aldosterone
excretion (B) to the concurrent daily rate of
urinary sodium excretion. The dashed lines
define the normal channel derived from the
study of normotensive people. A total of 219
patients with untreated essential hypertension
were studied, some on several occasions at
different levels of sodium intake. A, low-renin
essential hypertension; 0, nornial-renin
essential hypertension; U, high-renin essential
hypertension. Three major subgroups are
defined by the appropriateness or normality of
the plasma renin activity in relation to the rate
of sodium excretion, which is used as an
index of dietary intake and of sodium balance.
Additional abnormal subgroups are defined
when aldosterone is included in the analysis.
(From: BRUNNER HR, GARCIA DL,
ANDERSON S: Glomeruli and blood pressure:
Less of one, more the other? Am J Hypertens
1:335—347, 1988.)
The renin system in essential hypertension
Can a subtle chronic excess of renin production relative to
sodium balance account for a sustained rise in blood pressure?
Proof that it can emerged nearly 2 decades ago from our
experiments in which angiotensin was infused continuously for
as long as 11 days in normal volunteers. This is illustrated by
the case of one of these, a 35-year-old woman [5]. Her blood
pressure rose slightly above normal (from 100/60 mm Hg to
130/65 mm Hg) and was held there by adjusting the infusion rate
as she ate a constant diet and walked around the ward.
In the first 4 or 5 days, aldosterone secretion increased from
200 to 800 pg/day and sodium retention resulted; the subject
had a markedly positive sodium balance, gaining about 2 kg in
weight. A direct renal effect of angiotensin II probably added to
the sodium retention. However, after about 4 or 5 days of
angiotensin infusion, classic "escape" occurred, and she no
longer retained sodium. Sodium balance remained at the new,
higher level as indicated by persistence of her weight gain and
by the large natriuresis and commensurate weight loss that
occurred after the infusion was stopped. I believe that the most
important observation of this study was that less and less
angiotensin was required, as the infusion proceeded, to main-
tain the same level of hypertension. After 5 days, only one-fifth
of the original infusion rate was needed to sustain the same
increment in blood pressure.
The clinical response to ACE inhibitors offers an even more
persuasive demonstration of the culpability of inappropriate
renin secretion in sustaining hypertension: blood pressure de-
creases dramatically in high-renin and many medium-renin
patients. Equally persuasive is the lack of response to ACE
inhibitors in overtly low-renin patients, whose hypertension
appears to be sustained instead by inappropriate sodium reten-
tion and ECF volume expansion and whose blood pressure falls
instead in response to salt-depletion strategies, alpha blockers,
or calcium-channel blockers.
Investigators and clinicians generally agree about the role of
the renin system in malignant or single-kidney renovascular
hypertension. In both, renal ischemia is perceived erroneously
by the local renal baroreceptors to signify systemic hypoten-
sion. The basis for this hypoperfusion, afferent arteriolar con-
striction in malignant hypertension, and renal artery stenosis in
renovascular hypertension, is readily apparent by biopsy and
angiography, respectively. The depressor and the plasma renin
responses to ACE inhibitors are usually quick and definitive.
Indeed, these responses are so helpful in diagnostic screening
that many patients formerly considered to have essential hyper-
tension are recognized as having a renovascular condition
curable by angioplasty [61.
In short, malignant hypertension is the extreme form of
"dry," vasoconstrictive, renin-mediated hypertension—a mal-
functioning, misinformed servocontrol system. At the other
extreme of the spectrum is primary aldosteronism, in which the
autonomous release of aldosterone from an adrenal tumor
causes excessive sodium retention, with its attendant vasocon-
striction induced by the sodium retention and ECF volume
expansion. In this "wet" form of hypertension, renin produc-
tion is markedly suppressed. The magnitude of the blood
pressure elevation can be similar in both forms of hypertension
and does not help identify the mechanism of vasoconstriction.
Nephron heterogeneity: possible mechanism
in essential hypertension
Between the extremes I just discussed lie patients with
essential hypertension. Whereas the pathophysiology of renin-
mediated, essential hypertension is not as apparent as that of
malignant hypertension, evidence does suggest that it is a
selective disorder of certain nephrons. The evidence is shown
in Figure 2, a reproduction of one of many such biopsies
obtained in the 1950s, when thoracolumbar sympathectomy
was performed in many patients with essential hypertension.
One can easily see the two impressively narrowed afferent
arterioles, a phenomenon that the investigators, after studying
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Fig. 2. Variation in the degree of local thickening of larger renal
arterioles with localized collagen deposits, shown as grey fibrillar
material. Grade LII renal arteriosclerosis. Masson stain X 150. (From
Ref. 6.)
approximately 1800 renal biopsy specimens, identified as the
hallmark renal vascular lesion of uncomplicated essential hy-
pertension [7]. However, the entirely normal arterioles of many
or most nephrons are equally impressive and highly significant.
In patients with typical Goldblatt-type hypertension, neph-
rons in the kidney with the stenotic renal artery have dimin-
ished blood flow and reduced perfusion pressure, and the
juxtaglomerular cells that produce renin become uniformly
hyperplastic and heavily granulated [81. These changes corre-
late with elevated plasma renin activity and underlie the char-
acteristic renin-dependent hypertension. The juxtaglomerular
cells of the contralateral kidney, which is not clipped and is
therefore well perfused, do not exhibit any hyperplastic
changes, and renin secretion by that kidney is markedly sup-
pressed.
This evidence suggests that if the focal afferent arteriolar
renal lesion characteristic of essential hypertension produces
ischemia and increases renin secretion by some nephrons, while
other normal nephrons have augmented renal blood flow and
suppressed renin secretion, then a situation among nephrons
would occur analogous to that between the two kidneys of
one-clip, two-kidney Goldblatt hypertension. This hypothesis is
supported by the observation that some juxtaglomerular cells
are significantly hyperplastic in kidneys of patients with essen-
tial hypertension [91, most notably when significant arteriolar
thickening is present. That this nephron heterogeneity may
have greater pathogenic culpability than can be attributed to
nephron loss and overt renal insufficiency is further supported
by the observation, from the same source, that only 8% of
glomeruli were obsolescent in patients with essential hyperten-
sion [9].
We now propose that in many patients with essential hyper-
tension, surely those responding in some degree to ACE
inhibition, the subpopulation of ischemic nephrons that retain
sodium and hypersecrete renin is responsible for the chronic
disruption of normal blood pressure control [2]. In effect,
hypertension occurs primarily because an inappropriate circu-
lating renin (any plasma renin in a hypertensive individual)
arising from the ischemic nephrons also impairs sodium excre-
tion in the normal hyperfiltering nephrons too, thereby creating
too much sodium-volume retention for the plasma renin level.
In the ischemic nephrons, GFR is reduced because of under-
perfusion due to arteriolar narrowing; the nephron's attempt to
overcome this hypofiltration by increasing the plasma renin
level to induce mote efferent arteriolar vasoconstriction is offset
by the compensating effects of healthy, adapting nephrons,
which have appropriately turned down their renin production.
But at the same time the adapting nephron, which is hyperfil-
tering, increases proximal sodium reabsorption because it is
exposed to an inappropriate amount of circulating angiotensin
II emanating from the ischemic, underperfused nephrons. This
adaptation impairs the compensating natriuresis and leads to
sodium retention and volume expansion that are inappropriate
to the aggregate plasma renin level, a sum of that provided by
ischemic and normal nephrons. The ACE inhibitors break the
cycle by reducing the renin output by the ischemic nephrons,
thus lowering All and permitting the healthy, adapting neph-
rons to excrete the previously retained sodium.
Plasma renin as a risk factor
More than 50 years ago, Winternitz showed that injections of
renin produced severe vascular damage in nephrectomized dogs
whose sodium balance could be expected to be maximally
positive [10]. Since that time much experimental and clinical
data have related plasma renin activity to vascular injury [11].
The evidence from humans began 30 years ago with studies
showing that human malignant hypertension is caused or sus-
tained by an abnormal renal-adrenal interaction causing excess
renin and aldosterone secretion [12, 13]. This condition is
associated with diffuse vascular damage and fibrinoid change.
Significantly, the entire syndrome can be reversed by specific
antirenin therapy [14—iS], which ameliorates the hypertension
and hyperaldosteronism, thereby reducing blood pressure and
allowing healing of the vascular damage.
The case for renin's culpability is also supported by numer-
ous studies which show that bilateral nephrectomy also can
reverse the malignant syndrome, normalize the blood pressure,
and lead to healing of the vascular disease [11. Patients with
curable renovascular hypertension due to renin excess also are
more prone than those with other forms of hypertension to
malignant vasculitis with vascular damage in the brain and heart
[19, 20].
Many other clinical situations associated with high plasma
renin levels are accompanied by striking vascular damage,
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Fig. 3. Plot of the incidence of myocardial
infarction related to the baseline plasma renin
level among 1717 patients with mild
hypertension followed for 8 years. The back
row presents those 967 patients who had one
or more known risk factors (high cholesterol,
smoking or diabetes). The front row presents
the heart attack rates for those patients who
had no such risk factors. The plasma renin
level appears as a powerful, continuous and
most pervasive risk factor, multiplying the
heart attack rate by more than threefold
among those who had other risk factors.
(These data extend the previous work cited in
Ref. 25.) The findings are further supported
by animal studies describing myocardial,
cerebral and renal lesions after injection of
renin or angiotensin. (Adapted from Ref. 34.)
stroke, or heart attack. These include scleroderma [21], renal
trauma, acute closure of a renal artery graft [1], or a renin-
secreting tumor [221. After receiving the angiotensin 11-blocking
agent saralasin for a brief period as a diagnostic test, 4 patients
with renal hypertension and hyperreninemia developed marked
rebound hypertension, with encephalopathy in 2 and coma in
one [23]. Finally, in patients with scieroderma, marked vascular
damage and early demise correlate with marked elevations in
plasma renin [21, 24].
We proposed as early as 1972 that a baseline PRA measure-
ment could help identify patients at risk of stroke or heart
attack. The basis for this proposal, a longitudinal study of 219
untreated patients with moderate to severe hypertension,
showed that those with a normal or high PRA had an 11% and
14% incidence, respectively, of heart attack or stroke [25].
During the same 5-year observation period, none of 59 consec-
utive patients with low-renin hypertension had either of these
complications despite a similar elevation of blood pressure and
left-ventricular hypertrophy in the two groups.
Other data further support the observation of different pat-
terns of vascular injury and risk between patients with high- and
low-renin hypertension. (1) Low-renin hypertension is usually
of longer duration, is often of even greater degree than that seen
in patients with high-renin hypertension, and is just as difficult
to normalize with drugs [11, 26]. Yet, patients with low-renin
hypertension had better renal function than did the patients
with either medium- or high-renin hypertension [26]. (2) Pa-
tients with high-renin hypertension also showed signs of he-
moconcentration: hemoglobin, hematocrit, and total protein
values were higher than in patients with low-renin hypertension
or normotensive controls [27]. (3) Young hypertensive blacks,
known to be most prone to severe hypertension with vascular
sequelae, almost always fall into the medium- or high-renin
groups, whereas the great majority of blacks over age 50 have
relatively milder disease and exhibit low renin levels [26].
These data suggest that patients with low-renin essential
hypertension (approximately 30% of the hypertensive popula-
tion) and patients with primary aldosteronism (approximately
1% of the hypertensive population) may have a relatively
benign type of hypertensive disease. Both these subgroups
exhibit a more appropriate renal-renin suppressive response to
systemic hypertension than do patients with high-renin and
medium-renin levels; accordingly their sodium balance is more
positive. It follows that, for a given level of hypertension, their
blood and extracellular fluid volumes, and therefore their tissue
perfusion, are likely to be greater than those in patients with
medium- or high-renin hypertension.
Newer experimental [28—33] and clinical [34] data also sup-
port the hypothesis that renin is a pathogenic factor for cardio-
vascular sequelae (heart attack and stroke) [28—33]. Studies
have shown that infusing rats with a moderately pressor dose of
angiotensin for several hours produces beaded constriction and
post-stenotic dilation with disruption of the endothelium of the
arterioles and leakage of plasma into the interstitium [28]. Such
short-term infusions in rabbits [29, 31] and rats [30] can produce
myocardial infarction [31]; electron microscopy reveals that the
ischemic cardiac changes produced in rats resemble those seen
in early myocardial infarction in humans [30]. Recent experi-
mental studies show that feeding potassium supplements to
stroke-prone hypertensive animals causes marked suppression
of plasma renin levels, a change that is closely associated with
marked protection from stroke even though blood pressure is
often unchanged [32]. Other studies using an ACE inhibitor to
block renin activity also produced marked protection from
stroke in animals in which blood pressures were not reduced
[33].
Our recently published clinical trial makes an unambiguous
association between the renin-sodium profile and the risk of
myocardial infarction [34]. The study prospectively followed
1717 subjects with mild to moderate hypertension over 8.3
years and found that the level of the pre-treatment renin profile,
measured in all subjects, was independently associated with the
risk of myocardial infarction (but not stroke or mortality from
all causes). The range of blood pressures in this work-site group
of subjects was similar among the three renin subgroups, and
similar modified stepped-care treatment was given to all without
reference to the baseline renin profile. The independent asso-
ciation overrode all other factors—age, gender, and race as well
as diabetes, smoking, and hypercholesterolemia (Fig. 3). Thus,
among the 750 subjects with no other risk factors, those with
Cholesterol  245 mg%
Current smoker or quit  10 yrs
Fasting blood glucose  140 mg%
Risk ac
Low
Rcckn
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Table 1. Laboratory workup of the hypertensive patient
Plasma renin value
Plasma potassium
Fasting glucose
Lipid profile
Serum urea, creatinine, and uric acid
24-hour urinary sodium and potassium
24-hour urinary microalbumin
Echocardiogram
Baseline electrocardiogram
Captopril test for medium- and high-renin patients (2.5 ng/mllhr)
high renin values had a sevenfold greater risk of myocardial
infarction than did those with low or medium values; con-
versely, no heart attacks occurred among the 241 patients with
low renin values. Altogether, the plasma renin level appears to
be a continuous variable directly related to risk of heart attack.
Moreover, even in those patients who had one or more of the
other risk factors (n = 967), high renin level increased the risk
of heart attack by 3.2-fold.
Diagnosis and treatment
The modem evaluation of every new hypertensive patient
requires delineation of the prevailing mechanism of long-term
vasoconstriction [2, 3] plus a search for all curable causes and
a full definition of target-organ status and related risk [35]. To
this end, the initial workup should include the measurement of
serum potassium, urea, creatinine and uric acid, 24-hour uri-
nary electrolytes and microalbumin excretion rate, and the PRA
indexed against the 24-hour urine sodium (the renin-sodium
profile). Target-organ appraisal and risk assessment are further
enhanced by a baseline electrocardiogram and echocardiogram
to assess left-ventricular status and by a fasting blood sugar and
a lipid profile (Table 1).
The ambulatory renin profile is the primary screen for curable
forms of hypertension because it is markedly suppressed in
primary aldosteronism and usually elevated (and never below
2.5 ng/mllhr) in curable renovascular disease. Accordingly, to
rule curable renovascular disease in or out in patients with an
elevated renin profile, we next administer the captopril screen-
ing test [5] or, alternatively, a trial of an ACE inhibitor. The
renin profile and the plasma renin response to captopril also
provide information about renin involvement and nephron
status. Together with the baseline laboratory data, these tests
are useful for defining pathophysiology, pace of disease pro-
gression, and prognosis and can aid one in planning specifically
targeted, simpler, long-term drug therapy (Fig. 4).
With the initial workup in hand, the physician is positioned to
achieve the primary pharmacotherapeutic goal of long-term
antihypertensive therapy: prescribing the fewest number of
drugs in the smallest effective amount and lowest frequency
[36]. Such a goal is particularly important in hypertension,
considering that every antihypertensive drug presents some
degree of risk and that long-term, possibly even lifelong,
therapy is required.
Patients with high renin values and without renovascular
disease are most certainly candidates for monotherapy with
either an ACE inhibitor or a beta blocker. Conversely, those
with very low plasma renin values or no blood pressure
response or plasma renin response to captopril [37] are defi-
nitely candidates for monotherapy with calcium antagonists,
diuretics, or alpha blockers. But whereas the renin profile
provides a valuable guideline for making an appropriate selec-
tion among antihypertensive agents, its predictive power is
strongest at the extremes of the range. At the middle ranges,
renin-mediated and sodium-related mechanisms can overlap
and may reflect an inappropriate interaction between the two,
with too much volume for the renin level or vice versa. Here
physicians may need to give both anti-renin and anti-volume
therapies to curtail the reactive influence of the untreated limb.
Drug response or lack of it [38, 39] is especially helpful in
classifying patients in the medium range of renin values, in
whom the renin profile has its least predictive value. This
approach also applies to patients in whom renin profiling is not
available. The strategy of informed empiricism involves the
single-file sequential testing of the major, mechanism-specific
drug types: an optimum response to a given drug provides
strong suggestive evidence about the underlying mechanism.
Renin dependency can be assessed with a single, oral test
dose of captopril. This simple and inexpensive test is useful for
the screening of renovascular hypertension [5], but one must
remember that the reactive rise in renin, rather than the blood
pressure response itself, is the main discriminator of renovas-
cular hypertension. Nevertheless, a dramatic decrease in the
blood pressure over 60 minutes confirms renin dependency, just
as a total lack of response generally indicates a nonrenin
vasoconstrictor mechanism. For patients with a medium- to
high-renin profile (PRA >2.5 ng/ml/hr) in whom the captopril
test confirms renin dependency but in whom curable renovas-
cular disease is not found, the current choice for first-line
therapy is an ACE inhibitor. The higher the baseline renin level,
the more dramatic the blood pressure correction. An additional
long-term effect is attained by superimposing an aldosterone
blocker to diminish sodium retention.
In the medium- to high-renin group, a reasonable alternative
first choice is a beta blocker. Although they may not be as
potent as ACE inhibitors in a given patient, beta blockers are
extremely effective in lowering renin secretion [14]; in certain
subgroups (for example, patients with tachycardia or coronary
disease), they also can reduce cardiac work and perhaps protect
from future coronary events. Further, unlike diuretic therapy,
monotherapy with beta blockers has been shown in controlled
trials to protect from coronary events, the major sequelae of
hypertension [40].
A low-renin profile suggests that a sodium-volume-related
factor is contributing to the diastolic hypertension. Historically,
the first choice for patients with this pattern was a diuretic, the
cornerstone of the traditional stepped-care empiric approach to
treating all essential hypertension. The diuretic combated the
reactive fluid retention caused by all the other older drugs,
which were added in "steps." However, reactive fluid retention
generally is not a problem with modem therapeutic agents.
Even in patients with low-renin hypertension, the newer cal-
cium antagonists and alpha-1-adrenergic blockers can be more
effective than diuretics. Calcium antagonists are especially
beneficial in low-renin patients, many of whom have sodium-
dependent vasoconstriction.
The finding of the selective effectiveness of calcium channel
antagonists in low-renin hypertension is also supported by work
showing that a calcium antagonist fails to block the pressor
action of angiotensin II while readily blocking norepinephrine
action [40]. The specificity of calcium antagonists for low-renin
hypertension is by no means absolute; these drugs often can
produce significant depressor responses in medium- and even
high-renin hypertension, possibly because increased cytosolic
calcium may be a final pathway for sustaining all forms of
vasoconstriction.
Calcium-channel blockers theoretically are more attractive
agents than diuretics because, like ACE inhibitors, they actu-
ally improve blood flow to the heart, brain, and kidneys as they
reduce blood pressure. Calcium-channel blockers, unlike di-
uretics, are not associated with dehydration, hemoconcentra-
tion, impotence, abnormal lipid profiles, hyperuricemia, and
azotemia. Indeed, the fact that long-term clinical trials utilizing
a diuretic-based regimen have often failed to show protection
against coronary artery disease may be attributable to some of
these very problems [38]. Preliminary evidence from long-term
controlled trials suggests that converting enzyme inhibitors [41]
and calcium-channel blockers [42] might afford cardioprotec-
tion.
Alpha-l-receptor blockers also maintain tissue flow as they
lower pressure. The best responders to alpha blockers, like the
best responders to calcium antagonists, are patients with low-
renin hypertension [43, 44]. The alpha-i-receptor blockers,
although less potent than the calcium-channel blockers, appear
to address the same vasoconstrictor mechanism, perhaps be-
cause of the close proximity of alpha and calcium receptors on
the cell membrane [45]. Combination of the two drug types can
produce additive effects [45, 46].
Plasma renin activity values above 8—10 ng/mllhr or under 1.0
ng/ml/hr reliably suggest selective and effective monotherapy,
but intermediate-range values are not as precise. In this inter-
mediate range, renin-mediated and sodium-related mechanisms
of vasoconstriction might overlap or function reciprocally.
Unfortunately, most patients with essential hypertension have
mid-range PRA values, and the clinician must resort to the
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less-precise empiric process, trying first renin system contain-
ment, then a natriuretic agent, then the two together. Even so,
armed with the PRA value, the physician can expedite the
empiric process.
Even more important than diuretics, calcium antagonists, and
alpha-l-adrenergic blockers are the ACE inhibitors. These are
the most specific of all medications available. Because a nega-
tive result is as informative as a positive one, one has good
reason to employ an ACE inhibitor first in an empiric trial
series.
The strongest immediate effect of converting enzyme inhibi-
tion is the opposition of angiotensin's direct vasoconstriction.
Over the longer term (2 to 3 weeks), the additional impact of
ACE inhibitors in blocking aldosterone secretion is also ex-
pressed; thus these agents work on the sodium-related side as
well. If after a few weeks ACE inhibition still does not lower the
blood pressure, one should stop the antirenin drug and pursue a
therapy targeted against the sodium-volume status of the pa-
tient. The choices, in order of preference, are calcium-channel
blockers, alpha-l-adrenergic blockers, and diuretics. Calcium-
channel blockers and alpha-i -adrenergic blockers, when effec-
tive, do not reduce the blood flow, as diuretics can. Also, as
noted, these agents do not produce the unwanted side effects
characteristic of diuretic therapy (potassium and magnesium
depletion, glucose intolerance, hyperlipidemia, hyperuricemia,
and cardiac arrhythmias). Of course, in many low-renin patients
who are overtly volume expanded, diuretic therapy remains
important. Spironolactone might be the drug of choice for these
patients because this approach avoids potassium and magne-
sium loss [47]. Moreover, a recent drug trial of diuretics in the
elderly with systolic hypertension [48, 49], generally a low-
renin population, has established that diuretic-based therapy
reduces morbidity and mortality. Since such evidence is not yet
available for newer agents, the physician can be assured that
the relatively inexpensive diuretics are a good first choice in
patients with overt hemodilution or fluid retention, phenomena
often present in obese and low-renin hypertensive patients.
Two important caveats should be observed when one applies
the empiric treatment process to patients with mid-range renin
values. First, the clinician should resist the temptation to add
other drugs when converting enzyme monotherapy seems inad-
equate at first. Converting enzyme inhibitors also suppress
aldosterone secretion, but because the effect of this action only
reaches its full expression slowly (endogenous aldosterone
activity accounts for at most 1% to 2% of daily renal sodium
reabsorption), several weeks can pass before the full benefits of
ACE inhibitors accrue in patients in whom sodium dependency
shares culpability with renin dependency. This component of
the ACE inhibitor's antihypertensive action resembles that of
spironolactone in the delayed onset of what eventually can be a
considerable depressor effect, an effect often greater than that
of full-dose thiazide diuretic agents [47],
Second, the clinician must be willing to try only one drug at
a time. Only a rigorous, systematic trial of monotherapies
provides information about the nature of the basic hypertensive
lesion and an understanding of the pathophysiology of the
hypertension. Superimposing one drug on another, as in the
stepped-care regimen, confounds analysis and causes many
patients to take non-therapeutic and possibly detrimental drugs
for life. A recent review of 1486 clinical trials showing that
many patients whose blood pressures were controlled by com-
bination therapy rather than by monotherapy most likely rep-
resents a summing of many patients who would have responded
separately to each element rather than to the combination [50].
That is to say, these patients, responding separately and spe-
cifically to the effective components in their antihypertensive
recipe, would have been better served had there been an
orderly effort at discovering which component of the combina-
tion prompted a response. Therefore one must be wary of older
reports, which primarily focus on the mean responses for
groups. Often hidden by this analysis is the fact that, within
such a group, very good responders are averaged with non-
responders and with patients who actually exhibit a pressor
response [50].
Fortunately, the 2 patients cited in the case presentations
here, both physicians, referred themselves to a facility trained
to carry out an up-to-date evaluation of their hypertension.
Without that, they might well have remained among the legions
of hypertensive patients on long-term, even lifelong, medication
inappropriate to the nature of their disorder and possibly more
detrimental to their health and lifestyle than no treatment at all.
Armed with a knowledge of renin system servocontrol and
the meaning of a plasma renin assay, today's physician can
efficiently quantify the renin-angiotensin and sodium-volume
elements in the hypertensive condition. Use of the PRA test,
combined with other baseline tests of target-organ damage,
enables one to choose the most effective and the simplest drug
regimen for achieving the goals of blood pressure control and
protection from heart attack, stroke, and renal failure. At the
same time the physician has defined the baseline cardiorenal
status, ruled out curable forms of hypertension, and gained
insight into prognosis.
Questions and answers
Da. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Thank
you very much, Dr. Laragh. Would you say a little about the
mechanisms through which you believe renin exerts its vascu-
lotoxic effect and also briefly address the tissue renin-angioten-
sin system?
Da. LARAGH: There are several levels of possible explana-
tions. In the grossest possible terms, any vasoconstrictor can
produce ischemia and tissue death. Any of you who have given
noradrenalin intravenously and seen it get out of the artery and
into the arm know that there have been disasters following such
infusions. Any vasoconstrictor can compromise oxygen supply
and produce anoxic phenomena and tissue toxins associated
with destruction of cells, and promote a myocardial infarction
in that way. Besides that, angiotensin is a member of a large
number of peptides shown to be "growth factors" that stimu-
late neointimal hyperplasia. This is a very exciting area for
molecular and cellular biologists. The pathways are not eluci-
dated, but some of the descriptive steps are well established. I
think noradrenalin can produce most of the ischemic damage
that occurs with angiotensin. There is one basic difference:
noradrenalin, except in the case of pheochromocytoma, never
gets turned on for very long. In contrast, patients with pheo-
chromocytoma are replete with vascular disease—heart attack,
stroke. It's a matter of the way the package is delivered.
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Angiotensin excess may be delivered constantly; noradrenalin
is not delivered like this so ischemic injury is less likely.
As far as the tissue renin proposal goes, I'm not a believer in
a cardiovascular tissue renin system, because I think there's
little or no good evidence that heart or vascular tissue can
synthesize renin. Until new evidence forces us to repeal the
laws of endocrinology, endocrine systems involving hormones
arise from the secretion of a single mother gland. Thus, the
pancreas is the body's only source of insulin, the thyroid is the
only source of thyroxine, and the juxtaglomerular cells of the
kidney are the only source of active plasma renin. Accordingly,
24 hours after binephrectomy, plasma renin and cardiovascular
tissue renin become undetectable, and the full range of anti-
renin system drugs (beta blockers, saralasin, converting en-
zyme inhibitors, renin inhibitors, and angiotensin II antago-
nists) no longer exhibit any depressor action.
It is true that many investigators including my wife, Dr. Jean
Sealey, who was one of the first to do so, have demonstrated
that there is renin in endocrine tissues—the placenta, ovaries,
adrenals, and pituitary. Thus, there is renin in the endocrine
steroid-making tissues, but it is not active renin, but rather
prorenin. There is also prorenin in plasma even after you take
out the kidneys. Thus certain extrarenal tissues can encode the
gene for renin, but until proven otherwise the product of renin
gene expression is all in the prorenin state. It appears that the
only tissue in the body that can process prorenin into active
renin is renal tissue. We have infused huge amounts of prorenin
into primates, and we can't produce a molecule of active renin
from that infusion that can be assigned to in-vivo conversion.
Again, the kidneys are the only known source of active renin.
Apparently, what has confused the issue is that many inves-
tigators have pointed out that the heart and vascular tissue
contain abundant renin substrate and converting enzyme lining
vascular endothelium. Therefore, it is reasoned that if these
components are present, there must be a local tissue renin
system. I don't think such reasoning is correct or relevant
because, to draw the analogy from classic endocrinology again,
all the downstream machinery for insulin is in every muscle of
the body, but none of us would be so rash as to call it a tissue
insulin system because we know that the mother source is the
pancreas. In the cardiovascular system, the only source of
renin, until proven otherwise, is the kidney. There is no tissue
renin system unless you want to say that the plasma renin goes
there and does its job. I believe that's what happens, but that's
not news. Thus plasma active renin, purely of renal origin, is
the only known initiator of the cardiovascular renin-angioten-
sin-aldosterone system.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Dr. Laragh, for
the most part, you discussed the vasculotoxic effect of renin in
cardiovascular disease, that is, myocardial infarction and
stroke. What is the evidence incriminating renin as vasculotoxic
within the kidney itself? Second, how could we best prevent
such damage, not so much in malignant hypertension, but in
patients with benign hypertension?
DR. LARAGH: The evidence is partly circumstantial, but our
group and also Dr. Stier and colleagues have shown that in the
SHR stroke-prone rat, which ends up with severe heterogenous
nephron damage and renal disease much like that in the human,
the renal lesion appears to begin with diffuse multifocal isch-
emic changes in certain glomeruli [32, 33]. If you treat such an
animal with either an angiotensin II antagonist or a converting
enzyme inhibitor, even if you don't lower the blood pressure,
the kidney remains normal pathologically for as long as 12
weeks, whereas in the control animals, severe renal damage
develops.
This vascular protection also has been shown by Flecken-
stein using calcium antagonists, but much larger doses were
required [51]. This problem raises the issue of whether it's the
pressure correction per se or some unique effect of hormonal
antagonism at play. It's hard to separate this out. The data
suggest to me that pressure per se cannot explain this vascular
injury. Tobian believes this too [52]. The protection of the renal
architecture that he gets with potassium feeding in stroke-prone
SHR rats is dramatic, and it occurs without a fall in blood
pressure, but it is associated with a dramatic fall in plasma renin
[32]. Again, it's hard to completely dissociate pressure damage
from humoral damage. We need to learn more about the
pathways for humoral damage and how they work.
DR. JAMES STROM (Chief, Nephrology Division, Sr. Eliza-
beth's Hospital, Brighton, Massachusetts): When you de-
scribed a plasma renin of 2.5 ng/mllhr as a cut-off level, did that
require indexing for urinary sodium excretion?
Da. LARAGH: That number doesn't need to be related to
urinary sodium excretion. This is because nearly all our patients
select the same range of salt intake, creating a urinary sodium
between 80 mEq and 130 mEq/day. In 80 consecutive cases of
unilateral renovascular hypertension that we've had in the last
S years, we have never seen a patient with renovascular
hypertension whose plasma renin was less than 2.5 nglmllhr.
That's a good deal higher than low-renin essential hypertension
(values <0.8 nglmllhr). We used the plasma renin per se as a
screening test, without requiring knowledge of the urine so-
dium. If the renin is below 2.5 ng/mllhr (the lower, the more
convincing), we never do a workup for unilateral renovascular
disease.
DR. STROM: Do data suggest that patients with high-renin
hypertension who are appropriately treated with drugs that
reduce angiotensin levels have a blunted cardiovascular mor-
bidity and mortality rate?
DR. LARAGH: No, that is a critical untested question. Now
that we have 30 or 40 different commercially available drugs
that can effectively lower the blood pressure, the real goal of
treatment is not reducing blood pressure per se but protecting
patients from morbid events, that is, stroke and heart attack,
which reduce the duration and quality of life. Coronary events
in particular account for about 80% of the added morbid burden
of having hypertension. There is, so far, little established
cardiac benefit from drug treatments. By contrast, stroke pre-
vention is highly significant, but it too falls short of the
predicted goal.
What we badly need is a prospective morbidity/mortality trial
to see whether one drug type is better than another for
cardioprotection. So far the only drugs that have convincingly
protected from coronary events or stroke in humans are the
beta blockers and diuretics, respectively. Therefore, if you go
strictly by the books, you would say a physician is obliged to
use a beta blocker and diuretic combination in all patients. One
problem with such reasoning is that the world would never
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progress and we could never improve on an only partially
effective strategy.
The fact is that most clinical trials employing a diuretic-based
stepped-care regimen to lower blood pressure have failed to
show any significant reduction in coronary events (myocardial
infarction, ischemic episodes, left-ventricular hypertrophy, and
sudden death). At the same time, a large body of evidence has
accummulated indicating that beta-blocker therapy is highly
effective for preventing myocardial reinfarction. The benefits of
beta blockers likely involve a marked suppression of plasma
renin with reduced afterload as well as reduced cardiac work,
the blockade of epinephrine, and an antiarrhythmic action. In
fact, the success of the recent SHEPS trial in showing for the
first time some promise of cardioprotection in treated elderly
hypertensives might be due in part to the frequent use of a beta
blocker with the diuretic [49].
The more recently reported SOLVD and SAVE trials, in
which converting enzyme inhibitors were evaluated in conges-
tive heart failure, are also especially relevant to the renin
hypothesis [53, 54]. An unexpected fallout from both these
studies was the finding that the converting-enzyme-inhibitor-
treated groups experienced highly significant reductions in the
myocardial infarction rate. These data may be describing the
interruption of a renin mechanism important in the pathogenesis
of heart attack.
All these observations point out the need for a definitive
clinical trial in which different types of antihypertensive agents
that reduce blood pressure similarly are compared for their
effectiveness in protecting from coronary events and stroke.
Meanwhile, in the absence of such data, considerable evidence
suggests that the two drug classes that oppose renin system
activity, beta blockers and converting enzyme inhibitors, might
be selectively valuable for preventing cardiac damage and
attendant morbid events.
DR. AJAY K. SINGH (Division of Nephrology, New England
Medical Center): You have shown us elegant data supporting
the hypothesis that elevated renin levels might contribute
significantly to myocardial and vascular morbidity. However,
other factors such as obesity, tobacco use, diabetes, and
hyperlipidemia are also likely to be important. Did you exclude
patients who had diabetes mellitus, obesity, or were smokers?
Further, were patients matched for serum cholesterol and
components of their lipid profile?
DR. LARAGH: Tobacco, diabetes, and hyperlipidemia are
known risk factors, as you mentioned. In our study, we verified
the impact of these. However, we also verified the fact that
about half of the myocardial infarctions in the U.S. occur in
patients who do not have hyperlipidemia, diabetes, or tobacco
usage. It was in this so-called low-risk group that the plasma
renin value per se emerged, even more potently associated with
the occurrence of a myocardial infarction. Furthermore, in 241
consecutive low-renin hypertensive patients without other risk
factors, we have not yet observed a single myocardial infarc-
tion. In our study of this low-risk group, total cholesterol and
blood sugar values were similarly normal or low within the
three renin subgroups, so that renin stands alone as a risk
predictor in this group.
DR. MADIAS: I should note that vascular complications are
not rare in primary hyperaldosteronism, the extreme hy-
poreninemic state. In one series, approximately 25% of the
patients had suffered strokes and heart attacks over a mean
period of observation of about 6 years [55]. It would be of
interest to examine these data in the context of the presence of
other cardiovascular risk factors.
DR. LARAGH: Yes, that is true. However patients with
primary aldosteronism, unlike those with low-renin essential
hypertension, exhibit very high aldosterone levels, and this
excess per se is likely involved in vascular damage, just as it is
in experimental models, albeit at a much slower pace than renin
excess.
DR. RICHARD LAFAYETTE (Division of Nephrology, New
England Medical Center): I would like to return to the issue of
nephron heterogeneity. You have demonstrated areas of vas-
cular injury in kidneys of animal models and postulated the
same in patients with high renin levels who subsequently
develop target-organ damage. Is it possible that it is the
vascular injury that leads to the high-renin state as opposed to
the renin leading to excess mortality?
DR. LARAGH: This is a question often addressed since the
time of Homer Smith and Frank Byrom, who many years ago
asked, which comes first: the renal vascular disease or the
hypertension? It is possible that hypertension might start as a
diffuse (or just renal) vascular disease leading to inappropriate
renjn release and more vascular disease—the so-called vicious
circle, or the reverse sequence is possible. (I prefer the latter.)
That is, inappropriate renin release from genetic or acquired
renal disease or from genetic or acquired abnormal nerve
signals to renin release might start the whole process. Renal and
vascular biopsies even at the earliest stage have failed to settle
this question.
DR. MADIAS: Could you briefly address the possible role of
the vascular-endothelium-derived vasodilators and vasocon-
strictors in the pathogenesis of hypertension? After all, angio-
tensin is not the most potent vasoconstrictor that we now
recognize. Further, it has been shown that angiotensin itself can
stimulate the production of endothelin [56].
DR. LARAGH: The explosion in our knowledge of endothelial
function and the characterization of vascular endothelium as an
organ is one of the most exciting new aspects of circulatory
homeostasis of the past decade. We don't know where these
new humors fit. I'm referring to endothelin and nitrous oxide. I
think preliminary evidence is strong: angiotensin can affect the
endothelium; bradykinin can affect nitric oxide; and other
vascular factors not yet identified also might be involved. The
nitric oxide story is fascinating because it could be that the
nitric oxide vasodilator system is a local tissue mechanism for
offsetting vasoconstrictor hormones such as angiotensin, endo-
thelin, and thromboxane. We need more information.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I have two questions regarding the
hypothesis of nephron heterogeneity and renin production as
the cause of essential hypertension. (1) How do we test that
hypothesis? (2) How do we explain the difference between
high-renin and low-renin essential hypertension based on that
hypothesis?
DR. LARAGH: We are working on several ways, one of which
is using isotope technology to measure the mean transit time of
various isotopes across the kidneys. When there is nephron
homogeneity, you get a nice Gaussian curve. If some nephrons
have delay, you can show a flattening of the curve or a second
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peak. We have been able to show that result in some patients
with high-renin hypertension and in SHR. In the rats we have
evidence for the existence of nephron heterogeneity much like
that which we postulate in humans. That's one strategy. One
also can characterize this heterogeneity from perfusion of the
isolated SHR kidney. We have a third way: the normal kidney
will turn off renin secretion completely if you raise the arterial
pressure. Of course we can't go around raising people's blood
pressure, but we can reduce renal renin secretion and commen-
surately plasma renin levels by administering a beta blocker
and/or feeding salt. We think that in the patient with nephron
heterogeneity, a beta blocker does not lower the plasma renin
nearly as well as it does in the normal person. Generally, beta
blockers reduce plasma renin values by 75% or more for as long
as the drug is given. If I take a beta blocker, my renin goes
down to 0.11 ng/mllhr—a very low plasma renin level. Patients
with essential hypertension and nephron heterogeneity have a
subpopulation of ischemic nephrons that cannot suppress renin
secretion completely because of a persistent baroreceptor stim-
ulus downstream from their narrowed afferent arterioles. Thus,
there is the potential to describe nephron heterogeneity clini-
cally and relate it in part to autonomic activity.
In the grossest terms, the high-renin hypertensive patient
can't turn off renin secretion and thus has renin in the blood
inappropriately. The patient either stays hypertensive because
of the high renin or, to offset this, begins a salt diuresis. We
have no trouble explaining why this patient has hypertension—
the plasma renin elevation cannot be offset by salt excretion. If
we create that situation in an animal model it ends up always
hypertensive. We have trouble explaining why the renin doesn't
turn itself off and why it is turned on.
In low-renin disease, renin is not completely turned off either.
It's pretty low, but usually not totally suppressed. We believe
that such residual renin can be important pathogenetically
because if you block it with an ACE inhibitor, you can bring the
pressure down. Low-renin disease poses the question of
whether the hypertension is just from pure sodium-volume
retention, or this plus inappropriate small residual renin secre-
tion, or third, is there something we are missing—a lack of a
vasodepressor lipid, a lack of ANF, a lack of nitric oxide. This
and other local hormones need to be considered. How a body
sodium-volume excess translates into arteriolar vasoconstric-
tion is still an unsolved question. Whether it involves underac-
tivity of the nitric oxide system, increased calcium entry into
cells, or other mechanisms remains to be established.
DR. DAVID CAHAN (Chief, Division of Nephrology, Faulkner
Hospital, Boston, Massachusetts): I have two questions. One
large population with low-renin hypertension is the elderly
black population. Our impression is that these patients have
quite a few strokes and myocardial infarctions, particularly
strokes, as they age. Often these events occur at a younger age
than comparable events in the white population. Have there
been any studies to indicate that this population might evolve
into a population with higher-renin hypertension as the inci-
dence of stroke rises? A similar population to study might be
patients with primary aldosteronism.
DR. LARAGH: It's a critical question. I have never seen the
leopard change its spots. By that I mean that hypertensive
patients and also normotensive people tend to retain their
plasma renin pattern when studied repeatedly over 5 to 8 years
or longer. If a patient would change from low to high, as you
say, we'd have to examine that phenomenon very carefully.
However, from all that's ever been published, it appears that
plasma renin falls gradually with advancing age.
Now let me address your question about blacks, strokes, and
heart attacks. There appear to be at least two populations of
blacks. The younger black, 20 to 40 years old, can develop
severe vascular disease with renal failure and stroke but not
often heart attack. This group often ends up on dialysis, and
many of these patients, if not all, have medium to very high
renin values. At least some have had nephritis or collagen
disease.
In contrast the older hypertensive blacks, older than 50 years
of age, often have low-renin, salt-sensitive hypertension. These
patients have much less coronary disease than do white males
and they are often well treated by diuretics. Longevity may not
be impaired. Strokes occur but are usually associated with
advancing age.
DR. CAHAN: I have another question, one relating to the
profiling of patients who have hypertension. In the 1990s, as a
practitioner, I might be hesitant to profile people by discontinu-
ing their medications and measuring their renin profile versus
sodium excretion after a drug-free interval of 3 or 4 weeks. How
do you profile patients in a manner that is medically and legally
acceptable to society?
DR. LARAGH: I live in the same world that you do. First of all,
there are two kinds of patients—there's the type that is doing
well and feels fine on drug therapy. This is a non-issue. I'm not
going to discontinue that patient's therapy and do a renin
profile. Whenever you decide to stop drugs and re-evaluate,
you're usually provoked by the fact that the patient is unhappy
on the drugs, the therapy is ineffective, or both. These are the
only patients I take off drugs. It turns out that reducing and
eliminating drugs in this group is not actually difficult. Blood
pressure may improve as the drugs are stopped. As we saw in
the patient presented today, it is rational to discontinue medi-
cation in a patient with low renin activity who is taking
enalapril, 40 mg/day, and is still hypertensive. The reason the
plasma renin rises in the presence of ACE inhibitors is because
the blood pressure falls. If the ACE inhibitor isn't working, the
renin measurement is very powerful because it's low or un-
changed. You know you've wasted your money and the pa-
tient's because that's how the servocontrol works. Everybody
in whom an ACE inhibitor is working will exhibit a high plasma
renin level. It's a great index of compliance, and it's a great
index of the fact that the converting enzyme inhibitor is really
working. In renal vascular disease, the plasma renin can be
driven a lot higher by diuretics. Thus, in difficult situations, a
plasma renin measured on drug therapy can be meaningful
because very high or very low values can usually be rationally
explained.
DR. CAHAN: How about beta blockers?
DR. LARAGH: As one might expect, beta blockers can sup-
press or correct unilateral renovascular hypertension. The same
is true for converting enzyme inhibitors. However, if diuretics
are given concurrently, renin levels can rise reactively to a
point where the hypertension returns. In fact, it is useful to bear
in mind that any hypertension that is unresponsive to a diuretic
should be a renovascular suspect. The failure of subjects with
high-renin hypertension (for example, Goldblatt hypertension
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in humans or animals) to respond to diuretics is a consistent
phenomenon. The treatment just drives the renin higher and the
volume status lower.
DR. MADIAS: Your data on indexing renin and aldosterone
indicate that the aldosterone levels of patients with low-renin
hypertension is either normal or high. I believe this relationship
has been reported by others as well. Is there an explanation for
this relationship, and do you attribute any pathophysiologic
significance to it?
Da. LAltoH: The aldosterone often is inappropriately some-
what high in low-renin hypertension. I don't know who first
made that point, but George Thorn must have been one of the
first. Spironolactone is a very powerful and selective drug for
these people. In fact, Aldactone is one of the world's most
potent diuretics, one which I would say is grossly underappre-
ciated. It's been a hard sell because its very slow onset is
discouraging, not to mention its cost and the occurrence of
gynecomastia and impotence in higher dosages. However, in
much lower doses than originally used, it is a wonderful diuretic
and antihypertensive, and it maintains K and Mg + balance.
Aldosterone is too high in some low-renin patients. I agree with
that, and I'm particularly intrigued by the recent work of Karl
Weber, who is showing, contrary to the classic mineralocorti-
coid dogma, that there are mineralocorticoid receptors in many
places besides the kidneys, salivary glands, and colon. Weber
believes that aldosterone plays an important role in cardiac
remodeling after infarction by engaging fibroblast receptors and
activating fibrous tissue formation. If so, spironolactone ther-
apy might be relevant here too.
Reprint requests to Dr. J. Laragh, Chief, Cardiology Division, The
New York Hospital-Cornell Medical Center, 525 East 68th Street, New
York, New York 10021, USA
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